

SAFEEfficacious

MicroPulse® P3

GLAUCOMA DEVICE



Innovative Cyclophotocoagulation with MicroPulse Technology Powered by the New CYCLO G6™ Glaucoma Laser System



NON-destructive

ESSENTIAL

REPEAIABLE

NON-incisional

PREDICIABLE

ECONOMICAL









Excellent Safety Profile

The MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System enables a versatile procedure with multiple safety benefits:

- Non-Incisional
- Minimal to no inflammation post-op
- Patient downtime is significantly low
- Repeatable
- Predictable

2014 Randomized study shows MicroPulse P3 has similar IOP reduction as G-Probe with higher success rate and no hypotony¹

	MicroPulse TSCPC	TSCPC
Pre-op IOP	36.5 mmHg	35.0 mmHg
N Total of 48	24 pts	24 pts
Average Follow-up	17.5 months	17.5 months
IOP Reduction	45%	45%
Success Rate (≤21 mmHg at 18 months	75%	29%
Prolonged Hypotony	0	5
Mean # of Treatments	1.6	1.3



Pre Treatment.




Post Treatment with MP3. No detectable evidence of tissue damage.

lmages courtesy of A/Professor Paul Chew, NUHS

Proprietary MicroPulse® Technology

MicroPulse technology finely controls thermal elevation by "chopping" a continuous-wave (CW) laser beam into a train of repetitive short pulses allowing tissue to cool between pulses and reduce thermal buildup preventing visible tissue damage.



The MicroPulse P3 device has become an essential part of my armamentarium for use in glaucoma surgical procedures. It provides a very safe and efficacious solution for IOP control. I have used MicroPulse P3 for some of my most complicated cases but also I feel comfortable enough using it for patients with earlier disease in which we want to avoid a filtering bleb or the placement of hardware in the eye.

Robert Noecker, MD, MBA

Glaucoma Therapy Device Options

The patented MicroPulse® P3 and G-Probe™ devices are used to deliver laser energy for the treatment of glaucoma.



Efficacy - Confidence in IOP Control

Long-term results from National University Hospital (NUHS), Singapore prospective clinical study³:

- 33% IOP reduction at 18 months,
 N = 38 patients
- 61% med reduction (2.1 to 1.3)
- 73% success rate with 1.3 sessions

The MicroPulse P3 device has given me over 30% IOP lowering. With patients that are non-compliant with their medication, or we are really trying to keep off their medication, the MicroPulse P3 device allows me to treat patients more aggressively."




Steven Vold, MD

NUHS Prospective Clinical Study³



Multi-Center Retrospective Data^{2,4}



- 1. Aquino M, Barton K, Tan A, Sng C, Loon SC, Chew P. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. *Clin Experiment Ophthalmol*. 2015 Jan;43(1):40-6. doi 10.111/ceo. 12360 Epub 2014 Jun 21.
- Radcliffe N, Vold S, Kammer J, Ahmed I, Parekh P, Noecker R, Khatana A. MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) for the Treatment of Glaucoma Using the MicroPulse P3 Device. AGS. San Diego February 26 - March 1. 2015.
- 3. Tan A, Chockalingam M, Aquino M, Lim Z, See J, Chew P. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Experiment Ophthalmol. 2010;38(3):266-72
- Jeffrey Kammer, MD, Vanderbilt Eye Institute, Nashville, TN | Anup Khatana, MD, Cincinnati Eye Institute, Cincinnati, OH | Robert Noecker, MD, MBA, Ophthalmic Consultants of Connecticut, Fairfield, CT | Parag Parekh, MD, MPA, Laurel Eye Clinic, Brookville, PA Nathan Radcliffe, ND, Weill Cornell Medical College, New York, NY | Steven Vold, MD, Vold Vision, LLC, Fayetteville, AR



Specifications

Wavelength 810 nm infrared Weight 3.9 kg (8.5 lb)

Dimensions 27 cm x 29.5 cm x 19.7 cm (10.6" W x 11.6" D x 7.8" H)

Connector Type SmartProbe RFID with Laser Parameter Memory

Electrical 100-240 VAC, 50/60 Hz, <0.8 A

Cooling Air cooled

Exposure Duration CW-Pulse :: 10-9000 ms in 549 increments and continuous pulse up to 60 seconds

Exposure Interval CW-Pulse: 10-3000 ms in 542 increments and One Pulse

MicroPulse® Duration MicroPulse: 0.05-1.0 ms in 19 increments MicroPulse Interval MicroPulse: 1.0-10.0 ms in 90 increments

MicroPulse Duty Cycle Continuously adjustable from 0.5%-50%, and preset selections of 5%, 10%, and

15% duty cycles

Aiming Beam Diode laser, 635 nm nominal

Treatment Power 50-3000 mW, depending on delivery device

Additional Features

- Countdown Timer with audible/voice confirmations
- Programmable user presets for up to 10 individual presets
- Optional power-adjust wireless footswitch (wired footswitch included)
- Color LCD Touchscreen interface
- · Backlit control knobs and Treat/Standby button
- Optional Remote Control (high viewing angle, color LCD touchscreen)

Ordering

Product	Product Number	Units per Box
MicroPulse P3	15522	6
G-Probe™	15980	6
Laser Console	CYCLO-G6-SYSTEM	-

CYCLO G6 supports single-use devices only.

Specifications are subject to change without notice. IRIDEX, the IRIDEX logo and MicroPulse are registered trademarks and CYCLO G6, G-Probe and CW-Pulse are trademarks of IRIDEX Corporation. All other trademarks are the property of their respective owners.

Products are covered by one or more of the following U.S. patents: 5,511,085; 5,982,789; 6,327,291; 6,540,391; 6,733,490; 7,766,904; 7,771,417; 7,909,816; 5,997,498; 6,073,759; 6,092,898; 6,217,594; 6,494,314; 6,585,679; 6,726,666; 6,800,076; 6,866,142; 7,537,593; 8,177,777; 8,945,103; 783783; 69530497.6; KR 348012; 0904615; 69706541.3; CA 2331837; AU 759193; JP 4149670; EP 1009684; CA 2286002; JP 449444; JP 4570696; JP 4819754; JP 5123973; JP 5133069. U.S. and international Patents Pending may apply.

EC REP

Emergo Europ

Molenstraat 15, 2513 BH, The Hague, The Netherlands, Tel.: (31) (0) 70 345-8570, Fax: (31) (0) 70 346-7299

IRIDEX | 1212 Terra Bella Avenue | Mountain View, CA 94043 | 800.388.4747 (U.S. inquiries) info@iridex.com (U.S. & int'l inquiries) | www.iridex.com



